AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$CAI

Denton John Russel sold $239K of CAI

Denton John Russel (See Remarks) sold 7,500 shares of Caris Life Sciences, Inc. (CAI) at $31.82 ($0.24M total) on 2026-09-22.

Original reporting
SEC EDGAR · Denton John Russel
Published Sep 23, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CAI
Neutral
high confidence
Mentioned
$CAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAINeutralLow
01

Why it matters

The transaction is routine and unlikely to move the stock.

02

Market read

Minor insider sale with limited market relevance.

03

What to watch

Potential tax-driven liquidity event; no operational implications.

Relevance 4/10Novelty 4/10Timing: post-market 2026-09-22

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$CAINeutralHigh confidence
Context

Officer Denton John Russel sold 7,500 shares for $238,626 in a Form 4 filing.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is modest relative to total holdings and market cap; typical for routine diversification.

Market effects

Sector

None; the sale does not affect the broader biotech sector.

Regional

None; limited to the company.

Global

None.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings for pattern.

Key entities

  • Company
    Caris Life Sciences, Inc.

    Biotech firm focused on cancer diagnostics.

  • Officer
    Denton John Russel

    Company officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CAI insider trading history →

Related articles

SEP 23
$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

morningstar.com6 min
AUG 27
$CAIMedAI 8/10

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice

Caris Life Sciences (NASDAQ: CAI) published a study in npj Precision Oncology on an AI tool for pancreatic cancer treatment. The tool, part of the Caris Molecular Tumor Board Report, predicts patient outcomes for two treatments, with median survival of 16 months for FOLFIRINOX vs. 9.9 months for gemcitabine plus nab-paclitaxel. The company's MI Cancer Seek test, FDA-approved in November 2024, includes this tool.

proactiveinvestors.com2 min